官方服务：
资源简介：
Human gut metagenome sequences of metastatic breast cancer patients receiving pembrolizumab and eribulin
应用场景：
创建时间：
2023-12-11
相关数据集
Table_1_Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients.xlsx
BackgroundProgrammed death 1 (PD-1) and the ligand of PD-1 (PD-L1) are central targets for immune-checkpoint therapy (ICT) blocking immune evasion-related pathways elicited by tumor cells. A number of
NIAID Data Ecosystem50
Development and Analysis of a Stool Bank for Cancer Patients
This study is aimed at understanding the impact of gut microbiota on efficacy of cancer therapies, in particular checkpoint inhibitors, and using the resulting information to design microbial immunoth
NIAID Data Ecosystem20
Gut mictobiota composition correlation with the clinical outcome of NSCLC and RCC patients treated with anti-PD-1 mAB. Gut mictobiota composition correlation with the clinical outcome of NSCLC and RCC patients treated with anti-PD-1 mAB
Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizeable minority of cancer patients. Here, we show that primary resistance to ICI can be due
NIAID Data Ecosystem10
Fluctuations in gut microbiome composition during immune checkpoint inhibitor therapy
Programmed cell death protein-1 (PD-1)/PD-1 ligand-1 (PD-L1) blockade therapy, alone or in combination with chemotherapy, has shown remarkable promise for treatment of non-small cell lung cancer (NSCL
NIAID Data Ecosystem50
Gut microbiome of melanoma patients with a complete response to immunotherapy
Metastatic melanoma patients with a late complete response to immunotherapy exhibit different microbiome and dietary habits compared to early responders
NIAID Data Ecosystem10
